Letters in Drug Design & Discovery

G. Perry
University of Texas
San Antonio, TX
USA
Email: lddd@benthamscience.org

Back

Role of 2-Antiplasmin in Cardiovascular System

Author(s): En Shu, Hiroyuki Matsuno, Yasuo Kitajima, Osamu Kozawa.

Abstract:

Inhibition of the blood fibrinolytic system (plasminogen/plasmin) occurs either at the level of plasminogen activators, regulated by specific plasminogen activator inhibitors (PAIs) or at the level of plasmin, mainly regulated by α2-antiplasmin (α2-AP). In this contribution, we focused on the roles of α2-AP in acute myocardial infarction and vascular remodeling associated with cardiovascular diseases. Our findings have identified a new target for the development of new therapeutics for the clinical therapy of cardiovascular diseases.

Keywords: antiplasmin, myocardial infarction, re-endothelialization, vegf, vegfr-1

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 2
ISSUE: 3
Year: 2005
Page: [172 - 176]
Pages: 5
DOI: 10.2174/1570180053765129
Price: $58